What are the differences between embryonic, adult and induced pluripotent stem cells? Where do the experts expect the next medical application will be for stem cells? Do stem cells promote regeneration? How are cell types interacting? How can induced pluripotent stem (iPS) cells revolutionize drug discovery? Can cell therapies be made into a viable business? How close are we to finding the right business model? Are investors interested in stem cells today? What is the political and ethical landscape like now that the Obama administration has taken over the White House?
This is the Episode 1 of the Stem Cell
Parkinson’s Disease – Medical world has struggled in finding permanent cure for this condition that usually affects men over the age of 50 years, but now this maybe changing with the advent of stem cell based research in regenerative medicine. A significant clinical human trial using these technique now seems feasible in the near future.
Stem Cells and its Potential:
Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish
Understanding the genetic underpinnings of the biology of stem cells is crucial for their use in disease research and treatment. Scientists have identified a variety of genetic factors that maintain self renewal properties in embryonic, fetal, and adult stem cells. But whether these cell types are controlled by the same or different molecules is a persisting question.
Recent work from HSCI Principal Faculty Konrad Hochedlinger, PhD, begins to crack that mystery. Sox2 is a gene whose expression is required for maintaining pluripotency in early embryonic cells and regulating tissue development in the fetal stage. But until now, Sox2 expression had
Ever since human induced pluripotent stem cells were first derived in 2007, scientists have wondered whether they were functionally equivalent to embryonic stem cells, which are sourced in early stage embryos.
Both cell types have the ability to differentiate into any cell in the body, but their origins — in embryonic and adult tissue — suggest that they are not identical.
Although both cell types have great potential in basic biological research and in cell- and tissue-replacement therapy, the newer form, called IPS cells, have two advantages. They face less ethical constraint, as they do not require embryos. And they could
Scientists sporting white coats and safety gloves are working in a bright Food and Drug Administration (FDA) lab on an incredible project.
They are part of FDA’s MSC Consortium, a large team of FDA scientists studying adult mesenchymal stem cells (MSCs)—cells that could eventually be used to repair, replace, restore or regenerate cells in the body, including those needed for heart and bone repair.
The scientists’ investigational work is unprecedented: Seven labs at FDA’s Center for Biologics Evaluation and Research formed the consortium to fill in gaps in knowledge about how stem cells function (…)